It's hard to find a big name in health care that had a worse 2013 than Edwards Lifesciences (NYSE:EW). While the market's surged recently, Edwards's stock has plunged by more than 20%. Not only is this company facing sales of its innovative Sapien heart valve which look to fall below analyst expectations --it's also staring down competition that's eager to intrude on the U.S. market, where Edwards's Sapien currently is the only approved device of its type.
It's a desperate time for this hot name in medical devices, but is there a path for Edwards to rebound from its setbacks? The company this week won a big court case against competitor Medtronic (NYSE:MDT) over its rival's CoreValve device; Edwards is looking to keep its top opponent's device out of the U.S. market, which it's set to enter this year.
Is this too little, too late for Edwards, or can this stock mount a comeback? Find out in the video below, where Motley Fool contributor Dan Carroll takes you through all of the latest on Edwards Lifesciences's Sapien device -- and whether or not this innovative heart valve can spearhead a surprising surge in this struggling stock.
The innovative company you can't afford to ignore
Edwards has let investors down over the past year, but opportunities to get wealthy from a single investment don't come around often. However, they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.